Innovent's Q3 Product Revenue Climbs Over 40%; Chinaamc Hang Seng Hong Kong Biotech Index ETF (03069.HK) Rises 0.76% Intraday

NewTimeSpace News: As of 10:00 on October 29, 2026, Chinaamc Hang Seng Hong Kong Biotech Index ETF (03069.HK) rose 0.76% intraday to a latest price of HK$14.550, with a turnover of HK$58.65 million, a trading volume of 4.04 million shares, and a turnover rate of 1.83%. Its current net asset value per unit is HK$14.4312, and its assets under management stand at HK$3.18 billion.

NewTimeSpace understands that Chinaamc Hang Seng Hong Kong Biotech Index ETF (03069.HK) is managed by China Asset Management (Hong Kong), with the full name ChinaAMC Hang Seng Biotech ETF, and an investment objective of providing investment returns that closely track the Hang Seng Hong Kong-Listed Biotech Index, before fees and expenses. The ETF primarily adopts a full replication strategy, investing directly in securities within the Index in weightings broadly the same as their weightings in the Index; where restrictions or limited availability prevent the purchase of certain constituents, it will adopt a representative sampling strategy, under which the maximum deviation of any constituent from its Index weighting does not exceed 4%. The ETF may invest up to 5% of net asset value in money market instruments and cash deposits for cash management purposes; non-constituent securities held as a result of corporate actions by Index constituents are capped at 10% of net asset value; and it currently has no intention to use financial derivative instruments for hedging or investment purposes. The fund was established and listed on the Stock Exchange of Hong Kong on March 18, 2021, with a management fee of 0.40%. As of October 28, the ETF had assets under management of HK$3.18 billion and a net asset value per unit of HK$14.4312.

On the news front, Innovent Biologics (01801.HK) announced on October 29 that its product revenue for the third quarter of 2026 exceeded RMB 4.7 billion, up more than 40% year-on-year. The company said market penetration of key new products Xinerymei, Xinhile and Xinbimin continued to improve, while several tyrosine kinase inhibitors in its oncology portfolio achieved rapid sales growth, driving overall growth of the commercial portfolio. Innovent Biologics is a major constituent of the Hang Seng Hong Kong-Listed Biotech Index.

Guosen Securities believes that Chinese innovative drugs are entering a critical phase of global validation, with multiple Phase III datasets set to test their global competitiveness.